BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of Non-Compliance

Rhea-AI Summary

BIO-key International (NASDAQ: BKYI), a provider of Identity and Access Management solutions, has successfully regained compliance with Nasdaq listing requirements. The company had received a non-compliance notice on April 17, 2025, due to failing to timely file its Annual Report (Form 10-K) for the year ended December 31, 2024, violating Nasdaq Listing Rule 5250(c)(1).

The notification did not immediately affect BKYI's listing status on the Nasdaq Capital Market. The company resolved the issue by filing its Form 10-K on April 23, 2025, and received confirmation of compliance restoration from Nasdaq on April 24, 2025, officially closing the matter.

Positive

• Quick resolution of compliance issues (within 6 days)
• Maintained Nasdaq listing status without trading disruption

Negative

• Failed to meet SEC filing deadlines for 2024 Annual Report
• Received regulatory non-compliance notice from Nasdaq

HOLMDEL, N.J. , April 24, 2025 (GLOBE NEWSWIRE) -- BIO-key^® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced today that on April 17, 2025, it received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2024. The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.

On April 23, 2025, the Company filed its Form 10-K for the year ended December 31, 2024 with the SEC. On April 24, 2025, the Company received notice from Nasdaq stating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) and that the matter has been closed.

About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

Engage with BIO-key

	Corporate
	Facebook: LinkedIn: X:	https://www.facebook.com/BIOkeyInternational/ https://www.linkedin.com/company/bio-key-international @BIOkeyIntl
	Investors
	X: StockTwits:	@BIO_keyIR @BIO_keyIR

Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

FAQ

What caused BIO-key (BKYI) to receive a Nasdaq non-compliance notice in April 2025?

BIO-key received the notice for failing to timely file its 2024 Annual Report (Form 10-K) with the SEC, violating Nasdaq Listing Rule 5250(c)(1).

How did BIO-key (BKYI) resolve its Nasdaq listing compliance issue?

BIO-key resolved the issue by filing its 2024 Form 10-K on April 23, 2025, leading to compliance restoration on April 24, 2025.

Was BKYI's stock trading affected by the Nasdaq non-compliance notice?

No, the non-compliance notification had no immediate effect on the listing or trading of BIO-key's stock on the Nasdaq Capital Market.

What is Nasdaq Listing Rule 5250(c)(1) that BKYI violated?

This rule requires companies listed on Nasdaq to timely file all required periodic financial reports with the Securities and Exchange Commission.